Market closed

MannKind/$MNKD

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

$MNKD

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Danbury, United States

Employees

413

Website

www.mannkindcorp.com

MannKind Metrics

BasicAdvanced

$1.7B

77.32 $0.08

1.30 -

Price and volume

Market cap

$1.7B

Beta

1.3

52-week high

$7.39

52-week low

$3.17

Average daily volume

2.8M

Financial strength

Current ratio

4.545

Quick ratio

3.839

Long term debt to equity

-159.239

Total debt to equity

-165.16

Interest coverage (TTM)

1.60%

Management effectiveness

Return on assets (TTM)

9.12%

Return on equity (TTM)

-9.34%

Valuation

Price to earnings (TTM)

77.319

Price to revenue (TTM)

6.241

Price to book

-8.05

Price to tangible book (TTM)

-7.78

Price to free cash flow (TTM)

57.752

Growth

Revenue change (TTM)

51.35%

Earnings per share change (TTM)

-166.03%

3-year revenue growth (CAGR)

48.64%

3-year earnings per share growth (CAGR)

-37.41%

What the Analysts think about MannKind

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for MannKind stock.

MannKind Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

MannKind Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

MannKind News

AllArticlesVideos

MannKind Expands Executive Leadership Team

GlobeNewsWire·1 week ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Seeking Alpha·4 weeks ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

GlobeNewsWire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MNKD

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MannKind stock?

MannKind (MNKD) has a market cap of $1.7B as of January 15, 2025.

What is the P/E ratio for MannKind stock?

The price to earnings (P/E) ratio for MannKind (MNKD) stock is 77.32 as of January 15, 2025.

Does MannKind stock pay dividends?

No, MannKind (MNKD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next MannKind dividend payment date?

MannKind (MNKD) stock does not pay dividends to its shareholders.

What is the beta indicator for MannKind?

MannKind (MNKD) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.